Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials

References

• Dema B, Charles N. Advances in mechanisms of systemic lupus erythematosus. Discov Med. 2014 May;17(95):247–255.
   PubMedGoogle Scholar
• Squatrito D, Emmi G, Silvestri E, et al. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights. 2014 Sep;5(2):33–45. doi:10.1007/s13317-014-0058-y.
   PubMedGoogle Scholar
• Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013 04/04 06/14/received 01/11/accepted; 11:88–88. doi:10.1186/1741-7015-11-88.
   PubMed Web of Science ®Google Scholar
• Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther. 2012 May;34(5):1006–1022. doi:10.1016/j.clinthera.2012.02.028.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Doria A. Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty? Ann Rheum Dis. 2016 Feb;75(2):321–322. doi:10.1136/annrheumdis-2015-208312.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Urowitz MB. Clinical measures, metrics, and indices. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus and related syndromes. 8th ed. Philadelphia(PA): Elsevier/Saunders; 2013. p. 563–581.
   Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35. doi:10.1002/art.1780350606.
   PubMed Web of Science ®Google Scholar
• Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550–2558.
   PubMed Web of Science ®Google Scholar
• Symmons DP, Coppock JS, Bacon PA, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med. 1988 Nov;69(259):927–937.
   PubMedGoogle Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005 Jul;44(7):902–906. doi:10.1093/rheumatology/keh624.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168–1178.
   PubMed Web of Science ®Google Scholar
• Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15;61(9):1143–1151. doi:10.1002/art.24698.
   PubMed Web of Science ®Google Scholar
• Wallace D, Strand V, Furie R, et al. Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the British Isles Lupus Assessment Group-based composite lupus assessment endpoint [abstract]. Arthritis Rheum. 2011;63(Suppl 10):S885.
   Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014 Jan;73(1):183–190. doi:10.1136/annrheumdis-2012-202760.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288–291.
   PubMed Web of Science ®Google Scholar
• Kyttaris VC. New treatments for systemic lupus erythematosus. In: Tsokos GT, editor. Systemic lupus erythematosus basic, applied and clinical aspects. London(UK): Academic Press; 2016. p. 551–557.
   Google Scholar
• Leone A, Sciascia S, Kamal A, et al. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol. 2015 Jan;11(1):109–116. doi:10.1586/1744666X.2015.994508.
   PubMed Web of Science ®Google Scholar
• Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front Immunol. 2015;6:550. doi:10.3389/fimmu.2015.00550.
   PubMed Web of Science ®Google Scholar
• Jordan N, Lutalo PM, D’Cruz DP. Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus. Immunotherapy. 2015;7(3):255–270. doi:10.2217/imt.14.118.
   PubMed Web of Science ®Google Scholar
• Zhao L, Ye Y, Zhang X. B cells biology in systemic lupus erythematosus-from bench to bedside. Science China Life Sciences. 2015 Nov;58(11):1111–1125. doi:10.1007/s11427-015-4953-x.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222–233. doi:10.1002/art.27233.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215–1226. doi:10.1002/art.34359.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721–731.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918–3930. doi:10.1002/art.30613.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343–1349. doi:10.1136/annrheumdis-2011-200937.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013 Jan;22(1):63–72. doi:10.1177/0961203312465781.
   PubMed Web of Science ®Google Scholar
• Stohl W, Merrill JT, Looney RJ, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015;17:215. doi:10.1186/s13075-015-0741-z.
   PubMed Web of Science ®Google Scholar
• Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015 Sep;74(9):1667–1675. doi:10.1136/annrheumdis-2013-205144.
   PubMed Web of Science ®Google Scholar
• A study of the efficacy and safety of subcutaneous blisibimod in subjects with systemic lupus erythematosus (CHABLIS-SC1). ClinicalTrials.gov Identifier: NCT01395745. Bethesda (MD): National Library of Medicine (US); 2011.
   Google Scholar
• CHABLIS-SC2: A study of the efficacy and safety of subcutaneous blisibimod in subjects with systemic lupus erythematosus with or without nephritis. ClinicalTrials.gov Identifier: NCT02074020. Bethesda (MD): National Library of Medicine (US); 2014.
   Google Scholar
• CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis. Bethesda (MD): National Library of Medicine (US); 2015.
   Google Scholar
• Stohl W. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2014 Apr;18(4):473–489. doi:10.1517/14728222.2014.888415.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb;75(2):323–331. doi:10.1136/annrheumdis-2015-207653.
   PubMed Web of Science ®Google Scholar
• Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb;75(2):332–340. doi:10.1136/annrheumdis-2015-207654.
   PubMed Web of Science ®Google Scholar
• Robak E, Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Current Drug Targets. 2009 Jan;10(1):26–37.
   PubMed Web of Science ®Google Scholar
• Dorner T, Goldenberg DM. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag. 2007 Oct;3(5):953–959.
   PubMedGoogle Scholar
• Al Rayes H, Touma Z. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2014;8:2303–2310. doi:10.2147/DDDT.S49778.
   PubMed Web of Science ®Google Scholar
• Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8(3):R74. doi:10.1186/ar1942.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). 2013 Jul;52(7):1313–1322. doi:10.1093/rheumatology/ket129.
   PubMed Web of Science ®Google Scholar
• Strand V, Petri M, Kalunian K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford, England). 2014 Mar;53(3):502–511. doi:10.1093/rheumatology/ket378.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Hobbs K, Clowse ME, et al. Long-term safety and efficacy of epratuzumab in the treatment of moderate-to- severe systemic lupus erythematosus: results from an open-label extension study. Arthritis Care Res (Hoboken). 2016 Apr;68(4):534–543. doi:10.1002/acr.22694.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Wallace DJ, Furie R, et al. Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus: results from two phase 3 randomized, placebo-controlled trials [abstract]. Arthritis Rheumatol. 2015;67(suppl 10):2015.
   Google Scholar
• Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008 Sep;58(9):2652–2661. doi:10.1002/art.23732.
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase iii study. Arthritis Rheum. 2013;65(9):2368–2379. doi:10.1002/art.38037.
   PubMed Web of Science ®Google Scholar
• Cogollo E, Silva MA, Isenberg D. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2015;9:1331–1339. doi:10.2147/DDDT.S71276.
   PubMed Web of Science ®Google Scholar
• Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec;56(12):4142–4150. doi:10.1002/art.23047.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33. doi:10.1186/ar3738.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov;74(11):2006–2015. doi:10.1136/annrheumdis-2013-205067.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Ibanez D, et al. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol. 2011 Feb;38(2):275–284. doi:10.3899/jrheum.100724.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of atacicept in systemic lupus erythematosus (ADDRESS II). ClinicalTrials.gov Identifier: NCT01972568. Bethesda (MD): National Library of Medicine (US); 2013.
   Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct;62(10):3077–3087. doi:10.1002/art.27601.
   PubMed Web of Science ®Google Scholar
• Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol (Hoboken, NJ). 2014 Feb;66(2):379–389. doi:10.1002/art.38260.
   PubMed Web of Science ®Google Scholar
• Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 2013 Jun;65(6):1586–1591. doi:10.1002/art.37940.
   PubMed Web of Science ®Google Scholar
• ACCESS Trial group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol (Hoboken, NJ). 2014 Nov;66(11):3096–3104.
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Sharabi A, Molad Y, et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun. 2009 Aug;33(1):77–82. doi:10.1016/j.jaut.2009.03.009.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Isenberg DA, Wallace DJ. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med. 2015;2(1):e000104. doi:10.1136/lupus-2015-000104.
   PubMed Web of Science ®Google Scholar
• Schall N, Muller S. Resetting the autoreactive immune system with a therapeutic peptide in lupus. Lupus. 2015 Apr;24(4–5):412–418. doi:10.1177/0961203314556138.
   PubMed Web of Science ®Google Scholar
• Muller S, Monneaux F, Schall N, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008 Dec;58(12):3873–3883. doi:10.1002/art.24027.
   PubMed Web of Science ®Google Scholar
• Zimmer R, Scherbarth HR, Rillo OL, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013 Nov;72(11):1830–1835. doi:10.1136/annrheumdis-2012-202460.
   PubMed Web of Science ®Google Scholar
• A 52-week, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of a 200-mcg dose of IPP-201101 plus standard of care in patients with systemic lupus erythematosus (LUPUZOR). Bethesda (MD): National Library of Medicine (US); 2015.
   Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 Feb;62(2):542–552. doi:10.1002/art.27221.
   PubMed Web of Science ®Google Scholar
• Thanarajasingam U, Niewold TB. Sirukumab: a novel therapy for lupus nephritis? Expert Opin Investig Drugs. 2014 Oct;23(10):1449–1455. doi:10.1517/13543784.2014.950837.
   PubMed Web of Science ®Google Scholar
• Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011 Aug;72(2):270–281. doi:10.1111/j.1365-2125.2011.03964.x.
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013 Oct;65(10):2661–2671. doi:10.1002/art.38091.
   PubMed Web of Science ®Google Scholar
• Rovin B, van Vollenhoven R, Aranow C, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. 2016 Apr 25. [Epub ahead of print].
   Google Scholar
• Mathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015 May;75(8):835–846. doi:10.1007/s40265-015-0394-x.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905–1913. doi:10.1136/ard.2010.144485.
   PubMed Web of Science ®Google Scholar
• Zheng B, Yu XQ, Greth W, et al. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. Br J Clin Pharmacol. 2016 May;81(5):918–928. doi:10.1111/bcp.12864.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Mar 23. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y. A study to evaluate safety and tolerability of IV or SC dose of MEDI-545 in patients with systemic lupus erythematosus. ClinicalTrials.gov Identifier: NCT01031836. Bethesda (MD): National Library of Medicine (US); 2009.
   Google Scholar
• McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012 Nov;64(11):3666–3676. doi:10.1002/art.34632.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan;75(1):196–202. doi:10.1136/annrheumdis-2014-206090.
   PubMed Web of Science ®Google Scholar
• Guo X, Wang L, Illei G, et al. Anifrolumab differentially suppresses peripheral biomarkers of systemic lupus erythematosus compared with placebo in a phase IIb trial [abstract]. Arthritis Rheumatol. 2015;67(suppl):10.
   Google Scholar
• Brohawn P, Santiago L, Chris M, et al. Target modulation of a type I interferon gene signature and pharmacokinetics of anifrolumab in a phase IIb study of patients with moderate to severe systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2015;67(suppl):10.
   Google Scholar
• Furie R, Merrill JT, Werth VP, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2015;67(Suppl):10.
   Google Scholar
• Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011 Jul;80(1):17–28. doi:10.1038/ki.2010.483.
   PubMed Web of Science ®Google Scholar
• Touma Z, Urowitz MB. Systemic glucocorticoids. In: Tsokos GC, editor. Systemic lupus erythematosus. Harvard Medical School, Boston(MA): Elsevier; 2016.
   Google Scholar
• Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011 Jan;38(1):69–78. doi:10.3899/jrheum.100130.
   PubMed Web of Science ®Google Scholar
• Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005 Nov;125(5):889–894. doi:10.1111/j.0022-202X.2005.23889.x.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Ibanez D, et al. SLEDAI-2K responder index 50 captures 50% improvement in disease activity over 10 years. Lupus. 2012 Oct;21(12):1305–1311. doi:10.1177/0961203312454344.
   PubMed Web of Science ®Google Scholar
• Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort. Arthritis Rheumatol. 2015 May;67(5):1305–1313. doi:10.1002/art.39026.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Aranow C, Ginzler EM. Review of ACR renal criteria in systemic lupus erythematosus. Lupus. 2004;13(11):857–860.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797–808. doi:10.1002/acr.21664.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24;353(21):2219–2228.
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103–1112. doi:10.1681/ASN.2008101028.
   PubMed Web of Science ®Google Scholar
• Medina-Rosas J, Yap KS, Anderson M, et al. Utility of urinary protein creatinine ratio and protein content in a 24 hour-urine collection in lupus: systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2015 Dec 29. [Epub ahead of print].
   Google Scholar
• Birmingham DJ, Shidham G, Perna A, et al. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Ann Rheum Dis. 2014 Feb;73(2):475–476.
   PubMed Web of Science ®Google Scholar
• Medina-Rosas J, Gladman DD, Su J, et al. Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. Arthritis Res Ther. 2015;17:296. doi:10.1186/s13075-015-0808-x.
   PubMed Web of Science ®Google Scholar
• Isenberg D. Further thoughts about the ILLUMINATE studies of tabalumab in SLE. Ann Rheum Dis. 2016 Feb;75(2):e11. doi:10.1136/annrheumdis-2015-208709.
   PubMedGoogle Scholar
• Hahn S. Understanding noninferiority trials. Korean J Pediatr. 2012 Nov;55(11):403–407. doi:10.3345/kjp.2012.55.11.403.
   PubMedGoogle Scholar
• Touma Z, Urowitz MB, Ibanez D, et al. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol. 2014 Apr;41(4):688–697. doi:10.3899/jrheum.130005.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Su J, et al. Time to recovery of individual lupus manifestations on standard of care treatment. Arthritis Rheum. 2015;67(suppl 10). Abstract
   Google Scholar
• Touma Z, Gladman DD, MacKinnon A, et al. Development and assessment of users’ satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website. J Rheumatol. 2013 Jan;40(1):34–39. doi:10.3899/jrheum.120754.
   PubMed Web of Science ®Google Scholar
• Pike MC, Kelley L. Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? Curr Rheumatol Rep. 2012 Aug;14(4):324–333. doi:10.1007/s11926-012-0261-7.
   PubMed Web of Science ®Google Scholar